India's decision this month to produce Germany-based multinational Bayer's anti-cancer drug Nexavar, in the first use of "compulsory licensing" in South Asia, will save lives but also raises intricate questions. Under the compulsory licensing process, a government can under World Trade Organization (WTO) rules bypass a patent owner's rights after three years and order the manufacture and sale of life-saving medicines at much cheaper cost than by obtaining the medicine from...

India's use of the compulsory licensing provision under its patents law for the first time to make the patented cancer drug Nexavar available at affordable prices is an essential, although belated step to curb the mounting cost of drugs. The grant of the licence by the Controller-General of Patents, Designs and Trade Marks to Natco Pharma for manufacture of the drug Sorafenib Tosylate (Nexavar) to treat liver and kidney cancer is...

-The Times of India India has found a way to increase the number of doctors specifically to treat cancer. The Union health ministry will soon allow every professor of three disciplines - radiotherapy, medical oncology and surgical oncology - to teach three students as against the existing norm of two. Besides, associate professors across all specialities will be allowed to take two students under their wing as against one as per the...

Lack of trained manpower main hurdle, says health secretary More than a year after rolling out the national programme for prevention and control of cancer, diabetes, cardiovascular diseases and stroke, the Union Ministry of health and family welfare is still struggling to kick-start cancer screening in the district hospitals in the country. Health secretary P K Pradhan says lack of trained manpower is the biggest hurdle in starting the screening for different...

India recorded 9.8 lakh new cases of cancer last year, an increase of about 80,000 new cases as compared to 2009. Top cancer scientists from across the country along with Union health ministry officials and experts from the Indian Council of Medical Research (ICMR) met at the annual review meeting of the National Cancer Registry Programme in Guwahati to discuss the worrying trend over the last two days. This figure was...